Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.